ArticleAntimicrobial agents and chemotherapy2011
Cryptic species and azole resistance in the Aspergillus niger complex.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 130 citations in OpenAlex.
- Epidemiological Characteristics of ClinicalJournal of fungi (Basel, Switzerland) · 2026Article
- Article
- Prevalence ofJournal of fungi (Basel, Switzerland) · 2026Article
- Triazole Resistance and Misidentification of Aspergillus tubingensis in Southern California.JAMA network open · 2025Article
- Antifungal Minimal Inhibitory Concentrations of Mold Isolates from Patients with Cancer; Single-Center Experience, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- DecipheringMicrobiology spectrum · 2025Article
- Review
- Genomic divergence across the tree of life.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Pathogenic Aspergillus spp. and Candida spp. in coastal waters from southern Brazil: an one health approach.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- First documentation of Aspergillus welwitschiae in COVID-19-associated pulmonary aspergillosis in the Americas.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Superficial abdominal surgical site infection caused by Aspergillus welwitschiae: a case report.BMC infectious diseases · 2024Article
- Aspergillus hubkae, a Novel Species Isolated from a Patient with Probable Invasive Pulmonary Aspergillosis.Mycopathologia · 2024Article
- What do We Know about Cryptic Aspergillosis?Microorganisms · 2024Review
- cyp51A mutations, protein modeling, and efflux pump gene expression reveals multifactorial complexity towards understanding Aspergillus section Nigri azole resistance mechanism.Scientific reports · 2024Article
- Drug-ResistantPathogens (Basel, Switzerland) · 2023Review
- Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Resistance of Black Aspergilli Species from Grape Vineyards to SDHI, QoI, DMI, and Phenylpyrrole Fungicides.Journal of fungi (Basel, Switzerland) · 2023Article
- Virulence capacity of differentFrontiers in immunology · 2023Article
- Reducing the number of accepted species inStudies in mycology · 2022Article
- A Whole Genome Sequencing-Based Approach to Track down Genomic Variants in Itraconazole-Resistant Species ofJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus niger is a common clinical isolate. Multiple species comprise the Aspergillus section Nigri and are separable using sequence data. The antifungal susceptibility of these cryptic species is not known. We determined the azole MICs of 50 black aspergilli, 45 from clinical specimens, using modified EUCAST (mEUCAST) and Etest methods. Phylogenetic trees were prepared using the internal transcribed spacer, beta-tubulin, and calmodulin sequences to identify strains to species level and the results were compared with those obtained with cyp51A sequences. We attempted to correlate cyp51A mutations with azole resistance. Etest MICs were significantly different from mEUCAST MICs (P < 0.001), with geometric means of 0.77 and 2.79 mg/liter, respectively. Twenty-six of 50 (52%) isolates were itraconazole resistant by mEUCAST (MICs > 8 mg/liter), with limited cross-resistance to other azoles. Using combined beta-tubulin/calmodulin sequences, the 45 clinical isolates grouped into 5 clades, A. awamori (55.6%), A. tubingensis (17.8%), A. niger (13.3%), A. acidus (6.7%), and an unknown group (6.7%), none of which were morphologically distinguishable. Itraconazole resistance was found in 36% of the isolates in the A. awamori group, 90% of the A. tubingensis group, 33% of the A. niger group, 100% of the A. acidus group, and 67% of the unknown group. These data suggest that cyp51A mutations in section Nigri may not play as important a role in azole resistance as in A. fumigatus, although some mutations (G427S, K97T) warrant further study. Numerous cryptic species are found in clinical isolates of the Aspergillus section Nigri and are best reported as "A. niger complex" by clinical laboratories. Itraconazole resistance was common in this data set, but azole cross-resistance was unusual. The mechanism of resistance remains obscure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.